Vitreous floaters: to treat or not to treat? And how to treat?

Myodesopsias, also known as vitreous floaters, are a common condition, estimated to affect two out of three individuals[1]. They are a symptom of ageing, often related to posterior vitreous detachment (PVD), but may occur earlier in life in individuals with myopia. Thanks to the natural process of brain neuroadaptation, most people adjust to their presence, usually within 3 to 6 months from onset. However, some individuals report persistent, bothersome symptoms that heavily impact vision and quality of life.
A study by Wagle AM et al. found that patients with symptomatic floaters were willing, on average, to shorten their remaining life by 1.1 out of 10 years, and to take an 11% risk of death and a 7% risk of blindness to be relieved from the symptoms of floaters. Younger people were even more willing to take a risk of blindness[2].
More attention is given today to the visual and psychological distress caused by floaters, and more efforts have been made to increase awareness, understand the causes, classify the types and severity of floaters and explore potential treatment options.
There are currently four main approaches to floaters: no action (with or without micronutrients against oxidative stress and collagen glycation), atropine eye drops, YAG vitreolysis, and vitrectomy (complete or limited). All four approaches have different indications, have pros and cons and risks and benefits. And, currently, no consensus exists on whether, when and how to treat floaters.
In this “Expert Arena”, international thought leaders share their thoughts, experiences, and different approaches.
[1] Webb BF, Webb JR, Schroeder MC, North CS. Prevalence of vitreous floaters in a community sample of smartphone users. Int J Ophthalmol. 2013 Jun 18;6(3):402-5. doi: 10.3980/j.issn.2222-3959.2013.03.27. PMID: 23826541; PMCID: PMC3693028.
[2] Wagle AM, Lim WY, Yap TP, Neelam K, Au Eong KG. Utility values associated with vitreous floaters. Am J Ophthalmol. 2011 Jul;152(1):60-65.e1. doi: 10.1016/j.ajo.2011.01.026. Epub 2011 May 12. PMID: 21570045.
Michael Albrecht, MD
Feike Gerbrandy, MD
Sundaram Natarajan, MD
Aditya Jyot Eye Hospital, Mumbai, India
Niall Patton MB ChB, MD, FRCOphth
Manchester Royal Eye Hospital, UK